Healthcare

Imagion develops MagSense, an MRI imaging agent that uses non-radioactive, bio-safe magnetic nanoparticles. The company's stated aim is earlier and more specific cancer detection, with target applications in HER2-positive breast cancer, prostate cancer and ovarian cancer. It has no approved product, and clinical progress …

Osteopore makes 3D-printed, bioresorbable scaffolds for bone regeneration across several therapeutic areas, according to its half-year report. The company listed on the ASX on 23 September 2019. Its products span orthopaedic, craniofacial, dental and neurosurgical uses.

For the year ended 30 June 2026, Argent reportedRevenueof A$161,187, compared with A$180,565 a year earlier. The net loss narrowed to A$7.71 million from A$17.84 million, helped by lower administrative expenses of A$6.86 million andResearch and Developmentspending of A$0.49 million, down from A$3.59 million.

Visionflex combines its own hardware and software to connect third-party medical devices, so clinicians can run remote consultations. The company says hardware costs about A$5,000 to A$50,000 per unit, with software licensing of roughly A$5,000 a year. A new unattended access capability lets a …

Oakridge develops nurse call andAssistive Technologyhardware and software for hospitals, aged care, disability care and supported independent living, according to its 31 July 2026 quarterly report. Recent work includes installations, nurse call upgrades, wireless solutions and real-time location system implementations. Product development covers enterprise …

Adherium is based in Melbourne and describes itself as a provider of digital respiratory management. Its product is the US FDA-cleared Hailie Smartinhaler platform, which lets clinicians and patients remotely monitor inhaler use and adherence. The company states that it has sold more than …

According to the annual report, the GaRP-IBS Phase II trial did not reach statistical significance on its primary efficacy endpoint, the overall IBS Symptom Severity Score, although some secondary measures improved. The trial has been formally closed and the pre-clinical and clinical papers have …